CRT 2025

Panel Discussion | Our Understanding on the Pathophysiology and Mechanism of Atherosclerosis and the New Therapeutic Options

Panel Moderator(s)

• 

  Takashi Akasaka, MD, PhD

  Senior Consultant
  Nishinomiya Watanabe Cardiovascular Cerebral Center
  Nishinomiya, Hyogo, Japan

  Disclosure information not submitted.
• 

  Allen J. Taylor, MD

  Chairman of Cardiology
  MedStar Heart and Vascular Institute
  Washington, District of Columbia, United States

  Disclosure(s): Amgen: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Heartflow, Inc: Consultant (Ongoing)
• 

  Renu Virmani, MD

  President
  CVPath Institute, Inc.
  Gaithersburg, Maryland, United States

  Disclosure information not submitted.

Panel Discussant(s)

• 

  Paul T. Campbell, MD

  Interventional Cardiologist
  Sanger Heart & Vascular Institute
  Concord , North Carolina, United States

  Disclosure(s): No financial relationships to disclose
• 

  Charles German, MD, MS, FAHA, FASPC

  Assistant Professor
  Georgetown University

  Disclosure(s): No financial relationships to disclose
• 

  Ramzi Khamis, MD PhD

  Consultant Cardiologist. Clinical Director of Cardiology and Cardiothoracic Surgery
  Imperial College London and Imperial College Healthcare NHS Trust
  London , England, United Kingdom

  Disclosure information not submitted.
• 

  Peter Libby, MD

  Cardiovascular Specialist
  Brigham and Women's Hospital
  Boston, Massachusetts, United States

  Disclosure information not submitted.
• 

  Seth S. Martin, MD, MHS, FACC, FAHA, FASPC

  Professor
  Johns Hopkins
  Reisterstown, Maryland, United States

  Disclosure(s): Amgen: Consulting Fees (e.g., advisory boards) (Ongoing); Arrowhead: Consulting Fees (e.g., advisory boards) (Ongoing); Corrie Health: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing); Heartflow, Inc: Consulting Fees (e.g., advisory boards) (Ongoing); Merck: Consulting Fees (e.g., advisory boards) (Ongoing); New Amsterdam Pharma: Consulting Fees (e.g., advisory boards) (Ongoing); Novartis: Consulting Fees (e.g., advisory boards) (Ongoing); Verve Therapeutics: Consulting Fees (e.g., advisory boards) (Ongoing)
• 

  Nehal N. Mehta, MD, MSCE

  Clinical Professor of Medicine
  The George Washington University
  Washington, District of Columbia, United States

  Disclosure information not submitted.
• 

  Pedro R. Moreno, MD, FACC

  Director - Quality Assurance for Cardiology
  Mount Sinai Hospital
  New York, New York, United States

  Disclosure information not submitted.
• 

  Robert S. Rosenson, MD

  Director of Metabolism and Lipids
  Mount Sinai Health System
  New York, New York, United States

  Disclosure(s): Amgen Inc: Consulting Fees (e.g., advisory boards) (Ongoing); Arrowhead Pharmaceuticals, Inc.: Consulting Fees (e.g., advisory boards) (Ongoing); Avilar Therapeutics: Consulting Fees (e.g., advisory boards) (Ongoing); CRISPR Therapeutics: Consulting Fees (e.g., advisory boards) (Ongoing); Editas Medicine: Consulting Fees (e.g., advisory boards) (Ongoing); Eli Lilly and Company: Consulting Fees (e.g., advisory boards) (Ongoing); GSK: Consulting Fees (e.g., advisory boards) (Ongoing); Intercept Pharmaceuticals Inc: Consulting Fees (e.g., advisory boards) (Ongoing); Kowa American Corporation: Non-promotional lecture (Ongoing); Life Extension: Consulting Fees (e.g., advisory boards) (Ongoing); Lipigon Pharmaceuticals Inc.: Consulting Fees (e.g., advisory boards) (Ongoing); MediMergent LLC: Stock-privately held company (Ongoing); New Amsterdam: Consulting Fees (e.g., advisory boards) (Ongoing); Novartis: Consulting Fees (e.g., advisory boards) (Ongoing); Organon: Consulting Fees (e.g., advisory boards) (Ongoing); Precision BioSciences: Consulting Fees (e.g., advisory boards) (Ongoing); Regeneron Pharmaceuticals Inc.: Consulting Fees (e.g., advisory boards) (Ongoing); Rona Therapeutics, Inc.: Consulting Fees (e.g., advisory boards) (Ongoing); Ultragenyx Pharmaceuticals Inc.: Consulting Fees (e.g., advisory boards) (Ongoing); Verve: Consulting Fees (e.g., advisory boards) (Ongoing); Viatris: Non-promotional lecture (Ongoing); William Blair: Consulting Fees (e.g., advisory boards) (Ongoing); Wolters Kluwer: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing)
• 

  Habib Samady, MD, FACC

  President, Georgia Heart Institute
  Georgia Heart Institute, Northeast Georgia Health System
  Gainesville, Georgia, United States

  Disclosure information not submitted.